Cited by 796Epigenetics and DNA MethylationEffects and risks of endocrine disrupting chemicalsProstate Cancer Treatment and Research

Developmental Exposure to Estradiol and Bisphenol A Increases Susceptibility to Prostate Carcinogenesis and Epigenetically Regulates Phosphodiesterase Type 4 Variant 4

Open access
Ho, Shuk-Mei, Tang, Wan-Yee, Belmonte de Frausto, Jessica, Prins, Gail S.·2006·Cancer Research

Published version of a preprint

Abstract

Early developmental perturbations have been linked to adult-onset prostate pathology, including excessive exposure to estrogenic compounds; however, the molecular basis for this imprinting event is not known. An important and controversial health concern is whether low-dose exposures to hormonally active environmental estrogens, such as bisphenol A, can promote human diseases, including prostate cancer. Here, we show that transient developmental exposure of rats to low, environmentally relevant doses of bisphenol A or estradiol increases prostate gland susceptibility to adult-onset precancerous lesions and hormonal carcinogenesis. We found permanent alterations in the DNA methylation patterns of multiple cell signaling genes, suggesting an epigenetic basis for estrogen imprinting. For phosphodiesterase type 4 variant 4 (PDE4D4), an enzyme responsible for cyclic AMP breakdown, a specific methylation cluster was identified in the 5′-flanking CpG island that was gradually hypermethylated with aging in normal prostates, resulting in loss of gene expression. Early and prolonged hypomethylation at this site following neonatal estradiol or bisphenol A exposure resulted in continued, elevated PDE4D4 expression. Cell line studies confirmed that site-specific methylation is involved in transcriptional silencing of the PDE4D4 gene and showed hypomethylation of this gene in prostate cancer cells. Importantly, the PDE4D4 alterations in the estrogen-exposed prostates were distinguishable before histopathologic changes of the gland, making PDE4D4 a candidate molecular marker for prostate cancer risk assessment as a result of endocrine disruptors. In total, these findings indicate that low-dose exposures to ubiquitous environmental estrogens affect the prostate epigenome during development and, in so doing, promote prostate disease with aging. (Cancer Res 2006; 66(11): 5624-32)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-0516

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [2]Dodds EC, Lawson W. Synthetic estrogenic agents without phenanthrene nucleus. Nature. 1936;137:996–997. [Google Scholar]
  2. [44]Conti M, Swimnen JV. Structure and function of the rolipram-sensitive, low-Km cyclic AMP phosphodiesterase: a family of highly related enzymes. In: Houslay MD, Beavo JA, editors. Molecular pharmacology of cell regulation: cyclic nucleotide phosphodiesterase structure, regulation, and drug action. New York: Wiley; 1990. pp. 243–266. [Google Scholar]

Cited by

Sorted by citations

Authors
Ho, S.-M., Tang, W.-Y., Belmonte de Frausto, J., & Prins, G. S.
Affiliations
  • University of Cincinnati (US)
  • 2Department of Urology, University of Illinois at Chicago, Chicago, Illinois
  • University of Illinois Chicago (US)
Venue
Cancer Research
Published
2006-06-01
Volume
66
Issue
11
Pages
5624-5632
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1994048261
Cited by
796
References
53
Citations by year
2026: 6 · 2025: 10 · 2024: 21 · 2023: 22 · 2022: 21 · 2021: 36 · 2020: 24 · 2019: 34 · 2018: 30 · 2017: 44 · 2016: 47 · 2015: 65 · 2014: 38 · 2013: 67 · 2012: 63
FWCI
20.55
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • University of Illinois at Chicago
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 40890, R01DK040890)
  • National Institute of Environmental Health Sciences (ES12281, P30ES006096, R21ES012281, R01ES015584)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Effects and risks of endocrine disrupting chemicals
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Keywords
bisphenol A, estradiol, early life exposure, prostate cancer, epigenetic regulation, DNA methylation, endocrine disruptors, precancerous lesions, transcriptional silencing, CpG island hypomethylation, aging
MeSH terms
Bisphenol A Compounds, Animals, Animals, Newborn, Benzhydryl Compounds, Dose-Response Relationship, Drug, Estradiol, Female, Isoenzymes, Male, Phenols, Precancerous Conditions, Pregnancy, Prostate, Prostatic Neoplasms, 3',5'-Cyclic-AMP Phosphodiesterases, Rats, Sprague-Dawley, Genomic Imprinting, DNA Methylation, Genetic Predisposition to Disease, Epigenesis, Genetic, Rats, Cyclic Nucleotide Phosphodiesterases, Type 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review